NCT02858804 2026-02-11BDH-MCL01Institute of Hematology & Blood Diseases Hospital, ChinaPhase 4 Completed55 enrolled
NCT04626791 2024-03-12Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell LymphomaAcademic and Community Cancer Research UnitedPhase 2 Recruiting45 enrolled